A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Clinical trial NCT04995419 · COMPLETED
Trial details
- NCT number
- NCT04995419
- Sponsor
- Astellas Pharma China, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-22
- Primary completion
- 2022-05-13
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.